Protalix BioTherapeutics Inc. (NYSE:PLX) Q4 2021 Earnings Conference Call March 31, 2022 8:30 AM ET Company Participants Dror Bashan - President, Chief Executive Officer Eyal Rubin - Senior Vice President, Chief Financial Officer Charles Padala - LifeSci Advisors Conference Call Participants John Vandermosten - Zacks Small Cap Research Operator Good morning ladies and gentlemen and welcome to Protalix BioTherapeutics’ full year 2021 earnings conference call. At this time, all participants are in a listen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION | | | Page | | --- | --- | --- | | | PART I | | | | Cautionary Statement Regarding Forward-Looking Statements and Risk Factors Summary | 1 | | Item 1. | Business | 2 | | Item 1A. | Risk Factors | 32 | | Item 1B. | Unresolved Staff Comments | 58 | | Item 2. | Properties | 58 | | Item 3. | Legal Proceedings | 58 | | Item 4. | Mine Safety Disclosures | 58 | | | PART II | | | Item 5. | Market for Registrant's Common Equity, Related Stockholder M ...

Start Time: 08:30 January 1, 0000 8:48 AM ET Protalix BioTherapeutics, Inc. (NYSE:PLX) Q3 2021 Earnings Conference Call November 15, 2021, 08:30 AM ET Company Participants Dror Bashan - President and CEO Eyal Rubin - SVP and CFO Chuck Padala - LifeSci Advisors, IR Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2021 Financial Results and Business Update Confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware __65-0643773__ (State or other jurisdiction of incorpor ...

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q2 2021 Earnings Conference Call August 16, 2021 8:30 AM ET Company Participants David Holmes - LifeSci Advisors, Investor Relations Dror Bashan - President & Chief Executive Officer Eyal Rubin - Senior Vice President & Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Investments Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Second Quarter 2021 Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 001-33357 (Commission file number) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | registered | | -- ...

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q1 2021 Earnings Conference Call May 14, 2021 8:30 AM ET Company Participants Chuck Padala - LifeSci Advisors Dror Bashan - President & Chief Executive Officer Eyal Rubin - Senior Vice President & Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright John Vandermosten - Zacks Investments Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2021 Financial and Business Results Con ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware __65-06437 ...

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q4 2020 Earnings Conference Call March 30, 2021 8:30 AM ET Company Participants David Holmes - LifeSci Advisors Dror Bashan - President and Chief Executive Officer Eyal Rubin - Senior Vice President and Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright & Co. John Vandermosten - Zacks Investments Operator Good morning, ladies and gentlemen, and welcome to Protalix BioTherapeutics’ Fiscal Year 2020 Earnings Conference Call. ...

Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) P ...